Blueshift Asset Management LLC Acquires 1,290 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Blueshift Asset Management LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 53.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,716 shares of the medical research company’s stock after acquiring an additional 1,290 shares during the quarter. Blueshift Asset Management LLC’s holdings in IQVIA were worth $881,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Canada Pension Plan Investment Board increased its stake in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. Farallon Capital Management LLC lifted its position in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC increased its position in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. Impax Asset Management Group plc raised its stake in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after acquiring an additional 11,715 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IQV shares. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of IQV stock opened at $201.44 on Thursday. The firm has a market capitalization of $36.56 billion, a PE ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The company has a 50 day moving average price of $220.36 and a 200-day moving average price of $226.57. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.